The licensing agreement provides Pharmacells access to Moraga’s proprietary adult stem cell technology for banking its blastomere-like stem cells (BLSCs) that have been isolated, processed, and cryopreserved from the blood of individuals. Moraga’s scientists have found that its BLSCs are able to differentiate into most tissues and organs of the body.
John Wong, CEO of Moraga, said: “We are very pleased to have Pharmacells as our business partner to advance the company’s adult stem technology in the UK and Ireland. With Pharmacells, we believe we can continue to expand the use of our stem cell technology to other countries within the EU in the very near future.”